Moderna’s experimental flu vaccine more effective than approved shot in study

Moderna's experimental mRNA-1010 influenza vaccine demonstrated superior efficacy in a late-stage study, proving 26.6% more effective than GSK's approved shot in adults over 50, and 27.4% more effective in those over 65. This positive data led to a nearly 5% premarket jump in Moderna's shares, offering a crucial new revenue stream as the company navigates declining COVID vaccine sales and weaker-than-expected RSV vaccine uptake. The results position Moderna to address the critical need for more effective flu vaccines, with the company planning to engage regulators for submission.

Analysis

Moderna's late-stage trial results for its experimental influenza vaccine, mRNA-1010, represent a critical success for the company's product pipeline and revenue diversification strategy. The study demonstrated that the vaccine is 26.6% more effective than GSK's currently approved shot in adults aged 50 and older, with efficacy rising to 27.4% in the high-risk 65-and-older demographic. This positive data is a significant catalyst, reflected in the nearly 5% premarket share increase, especially as the company contends with declining COVID vaccine sales and weaker-than-expected uptake of its RSV vaccine. The results provide a fundamental counterweight to the stock's nearly 35% year-to-date slump, which has been partly attributed to political concerns. Furthermore, the timing aligns with a clear market need, as the recent flu season saw a 15-year high in hospitalizations, underscoring the demand for more effective vaccines. This successful efficacy trial now unblocks Moderna's strategy for a combination flu and COVID vaccine and sets the stage for the company to engage with regulators for market submission.

Key Decisions for Investors

• The superior efficacy data for mRNA-1010 significantly de-risks a key pipeline asset, providing a clear path to a new revenue stream that can offset declines in the COVID franchise, warranting a reassessment of Moderna's long-term growth trajectory.
• Given the vaccine's demonstrated 26.6% higher effectiveness over a key competitor's product, investors should anticipate Moderna capturing significant market share in the seasonal flu market, potentially justifying a long position in MRNA and a review of exposure to incumbent flu vaccine manufacturers like GSK.
• The next key catalysts will be the timing and outcome of regulatory filings for mRNA-1010; investors should also view this success as a positive leading indicator for the viability of the company's broader mRNA platform, including the planned flu and COVID combination vaccine.